Therapeutic subgroup
J01 – ANTIBIOTIKA ZUR SYSTEMISCHEN ANWENDUNG
- Anatomical main group J: ANTIINFEKTIVA ZUR SYSTEMISCHEN ANWENDUNG
14Decisions
36Patient groups
Added benefit by patient group
- Non-quantifiable1
- Deemed proven35
Subgroups
- J01A TETRACYCLINE 2 decisions
- J01D ANDERE BETA-LACTAM-ANTIBIOTIKA 9 decisions
- J01G AMINOGLYKOSID-ANTIBIOTIKA 1 decision
- J01X ANDERE ANTIBIOTIKA 2 decisions
Decisions, newest first
- 2026-08-06RecarbrioImipenem/Cilastatin/RelebactamDeemed proven: 3 of 3 patient groups
- 2026-07-16XeravaEravacyclinDeemed proven
- 2025-11-20XydalbaDalbavancinDeemed proven
- 2025-05-15ZaviceftaCeftazidim/AvibactamDeemed proven: 4 of 4 patient groups
- 2025-04-17VaboremMeropenem/VaborbactamDeemed proven: 5 of 5 patient groups
- 2024-12-05ExblifepCefepim/EnmetazobactamDeemed proven: 3 of 3 patient groups
- 2024-02-01XydalbaDalbavancinDeemed proven
- 2023-02-02ZerbaxaCeftolozan/TazobactamDeemed proven: 3 of 3 patient groups
- 2023-01-19XeravaEravacyclinDeemed proven
- 2022-11-03ZaviceftaCeftazidim/AvibactamDeemed proven: 5 of 5 patient groups
- 2022-11-03ZerbaxaCeftolozan/TazobactamDeemed proven: 4 of 4 patient groups
- 2022-11-03RecarbrioImipenem/Cilastatin/RelebactamDeemed proven: 3 of 3 patient groups
- 2022-05-05FetcrojaCefiderocolDeemed proven
- 2021-05-20Arikayce liposomalAmikacinNon-quantifiable
Data status: 2026-10-29